May 8, 2026 03:36AM Piper Sandler Downgrades Engene Holdings Inc. (ENGN) to Neutral

May 8, 2026 02:45AM Oppenheimer Downgrades Engene Holdings Inc. (ENGN) to Perform

May 8, 2026 02:33AM Guggenheim Downgrades Engene Holdings Inc. (ENGN) to Neutral

May 7, 2026 07:01AM enGene reports 54% response rate in bladder cancer gene therapy trial

May 1, 2026 09:18AM Piper Sandler Reiterates Overweight Rating on Engene (ENGN), 'under-the-radar NMIBC name'

Apr 13, 2026 07:08AM WBB Securities Starts Engene Holdings Inc. (ENGN) at Buy

Mar 23, 2026 05:55AM Engene Holdings Inc. (ENGN) PT Lowered to $9 at UBS

Mar 12, 2026 05:18AM Engene Holdings (ENGN) Reiterated at Market Outperform by Citizens After CEO Meet

Mar 10, 2026 06:43AM Engene Holdings Inc. (ENGN) PT Lowered to $27 at Guggenheim

Mar 9, 2026 10:16AM Raymond James Reiterates Strong Buy Rating on Engene Holdings Inc. (ENGN) following Q1 results

Feb 19, 2026 04:28PM Engene (ENGN) files $400M mixed shelf

Jan 30, 2026 02:37AM Jefferies Starts Engene Holdings Inc. (ENGN) at Buy

Jan 20, 2026 05:52PM enGene secures $125 million expanded debt facility with Hercules Capital

Jan 5, 2026 04:25AM Citizens Reiterates Market Outperform Rating on Engene Holdings Inc. (ENGN), Highlights 'Impressive Progress'

Dec 23, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Dec 22, 2025 04:04PM enGene completes LEGEND trial enrollment with 62% response rate, reports FY results

Dec 3, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Dec 2, 2025 07:30AM enGene selected for FDA manufacturing pilot program

Nov 12, 2025 07:31AM Engene Holdings Inc. (ENGN) PT Raised to $33 at Oppenheimer

Nov 12, 2025 04:54AM Engene Holdings (ENGN) PT Raised to $21 at Citizens on Detalimogene Safety Profile

Nov 12, 2025 04:25AM Engene Holdings Inc. (ENGN) PT Raised to $21 at Leerink Partners

Nov 11, 2025 09:31AM Raymond James Upgrades Engene Holdings Inc. (ENGN) to Strong Buy

Nov 11, 2025 07:30AM enGene reports 62% response rate for bladder cancer treatment

Sep 12, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Sep 8, 2025 07:16AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Sep 3, 2025 07:30AM enGene completes enrollment of 100 patients in bladder cancer trial

Jul 8, 2025 08:03AM enGene adds three board members and promotes executives for commercialization

Jun 25, 2025 08:00AM Engene (ENGN): FDA Grants RMAT Designation for Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Jun 16, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Jun 16, 2025 04:14AM Citizens JMP Reiterates Market Outperform Rating on Engene Holdings Inc. (ENGN)

Jun 12, 2025 12:59PM Raymond James Reiterates Outperform Rating on Engene Holdings Inc. (ENGN)

Jun 4, 2025 08:39AM Engene (ENGN) announces CMO resignation

May 28, 2025 07:30AM Engene (ENGN) Appoints Amy Pott as Chief Global Commercialization Officer

Apr 29, 2025 04:18AM Citizens JMP Reiterates Market Outperform Rating on Engene Holdings Inc. (ENGN)

Mar 11, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Engene Holdings Inc. (ENGN)

Mar 10, 2025 04:52PM Engene (ENGN) Tops Q1 EPS by 48c

Feb 17, 2025 11:52PM Piper Sandler Starts Engene Holdings Inc. (ENGN) at Overweight

Jan 6, 2025 02:00PM 7 top biotech picks for 2025 according to Wells Fargo

Dec 23, 2024 06:24AM H.C. Wainwright Starts Engene Holdings Inc. (ENGN) at Buy

Nov 18, 2024 02:31AM JMP Securities Starts Engene Holdings Inc. (ENGN) at Market Outperform

Oct 25, 2024 08:01AM Engene (ENGN) Announces $60 Million Private Placement Financing

Oct 21, 2024 08:45AM Engene (ENGN) Appoints Joan Connolly as CTO, Anthony Cheung as Chief Scientific Officer

Sep 27, 2024 06:26AM Oppenheimer Reiterates Outperform Rating on Engene Holdings Inc. (ENGN)

Sep 27, 2024 05:57AM Engene Holdings Inc. (ENGN) PT Lowered to $17 at Leerink Partners

Sep 26, 2024 12:44PM Morgan Stanley Reiterates Overweight Rating on Engene Holdings Inc. (ENGN)

Sep 24, 2024 06:35AM Oppenheimer Reiterates Outperform Rating on Engene Holdings Inc. (ENGN)

Aug 27, 2024 04:02PM Oppenheimer Starts Engene Holdings Inc. (ENGN) at Outperform

Jul 24, 2024 06:30AM Engene (ENGN) Appoints Ron Cooper as CEO

Jul 18, 2024 08:06AM NewAmsterdam Pharma (NAMS) Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors